Microbion Biosciences Microbion is a clinical-stage pharmaceutical company developing a novel class of compounds for the treatment of difficult-to-treat infections, including chronic infections and antibiotic-resistant infections
About Microbion Microbion is a clinical-stage pharmaceutical company developing a novel class of compounds for the treatment of resistant and difficult to treat infections
News - Microbion Latest news from Microbion Microbion is a clinical-stage pharmaceutical company developing a novel class of compounds for the treatment of resistant and difficult to treat infections
Our Technology | Microbion Microbion is developing innovative, site-specific delivery approaches for the prevention and treatment of infectious diseases by virtue of the broad-spectrum antimicrobial and anti-biofilm properties of the compounds derived from our novel platform technology
Pipeline - Diabetic Foot Ulcer Infection | Microbion Microbion is a clinical-stage pharmaceutical company developing a novel class of microbial bioenergetic inhibitors for the treatment of resistant and difficult to treat infections Subscribe to Our Newsletter
Microbion Awarded up to $17. 1 Million from CARB-X and the Cystic . . . – May 28, 2020 – Microbion Corporation of Bozeman, Montana today announced it has been awarded up to US$17 1 million from CARB-X and the Cystic Fibrosis Foundation to advance the development of its antimicrobial drug pravibismane for the treatment of cystic fibrosis (CF)-related pulmonary infections
Respiratory Infection | Microbion Microbion’s compounds with their dual antimicrobial and anti-biofilm properties, represent a unique approach to treating resistant, chronic CF infections Pre-clinical studies with an inhalation formulation of pravibismane, that will enable clinical studies, are ongoing
Microbions Team Microbion is a clinical-stage pharmaceutical company developing a novel class of microbial bioenergetic inhibitors for the treatment of resistant and difficult to treat infections Subscribe to Our Newsletter
Microbions Pravibismane Granted Second FDA Orphan Drug Designation for . . . Microbion's lead drug candidate, pravibismane, is the first product in this new class and has multiple novel modes of action, including potent broad spectrum anti-infective, antibiofilm, and anti-inflammatory activity, offering unique potential to address the unmet needs of chronic and severe health conditions